AssetMark Inc’s Eterna Therapeutics ERNA Stock Holding History

AssetMark Inc’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16	Hold	5	–	–	﹤0.01%	3753
2026 Q2	$33	Hold	5	–	–	﹤0.01%	3520
2026 Q1	$26	Hold	5	–	–	﹤0.01%	3419
2025 Q4	$160	Hold	5	–	–	﹤0.01%	3275
2025 Q3	$146	Hold	5	–	–	﹤0.01%	3097
2025 Q2	$245	Hold	5	–	–	﹤0.01%	2855
2025 Q1	$356	Buy	+5	New	+$617	﹤0.01%	2466

Other funds holding ERNA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Tradewinds Capital Management Bellingham, Washington $578M AUM 35.02% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

AssetMark Inc's ERNA Position: Q3 2026 in Review

AssetMark Inc held its Eterna Therapeutics (ERNA) position steady in Q3 2026 at 5 shares worth $16. The position accounts for ﹤0.01% of the portfolio, ranked #3753.

AssetMark Inc first reported a position in ERNA in Q1 2025 and has held it in 7 quarters since. The position peaked at $356 in Q1 2025. 7 funds tracked by Wall St. Rank hold ERNA as of Q3 2026.

AssetMark Inc held 5 shares of Eterna Therapeutics worth $16 as of Q3 2026.
AssetMark Inc left its Eterna Therapeutics share count unchanged in Q3 2026.
Eterna Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3753 holding.
AssetMark Inc first reported a position in Eterna Therapeutics in Q1 2025 and has held it in 7 quarters since.
AssetMark Inc's Eterna Therapeutics position peaked at $356 in Q1 2025.
7 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.